Cargando…

In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations

Objective To compare in vitro and in vivo biological and biochemical properties of five liquid intravenous immunoglobulin (IVIg) preparations licensed for therapeutic use in Europe. Methods ClairYg® was compared in a blinded manner to four other liquid IVIg preparations licensed in Europe (Octagam®,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhainaut, F, Guillaumat, P-O, Dib, H, Perret, G, Sauger, A, de Coupade, C, Beaudet, M, Elzaabi, M, Mouthon, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580880/
https://www.ncbi.nlm.nih.gov/pubmed/23003576
http://dx.doi.org/10.1111/j.1423-0410.2012.01648.x
_version_ 1782260338339610624
author Dhainaut, F
Guillaumat, P-O
Dib, H
Perret, G
Sauger, A
de Coupade, C
Beaudet, M
Elzaabi, M
Mouthon, L
author_facet Dhainaut, F
Guillaumat, P-O
Dib, H
Perret, G
Sauger, A
de Coupade, C
Beaudet, M
Elzaabi, M
Mouthon, L
author_sort Dhainaut, F
collection PubMed
description Objective To compare in vitro and in vivo biological and biochemical properties of five liquid intravenous immunoglobulin (IVIg) preparations licensed for therapeutic use in Europe. Methods ClairYg® was compared in a blinded manner to four other liquid IVIg preparations licensed in Europe (Octagam®, Kiovig®, Gamunex®, Privigen®). Three batches of each preparation were tested, except for the IgG repertoires and the animal model. Results Levels of anti-A and anti-B antibodies were lower in ClairYg® (0·11/0·11) relative to a positive EDQM standard and Octagam® (0·11/0·08) than in other preparations (0·33–0·69/0·42–0·46). IgG in ClairYg® recognized 365 and 416 protein spots in HEp-2 cell and Escherichia coli protein extracts vs. 230–330 and 402–842 protein spots, respectively, for IgG in other preparations. IgA content (301 vs. 165–820 ng/mg of IgG), Factor XI and Factor XII antigen (0·46 vs. 0·85–2·40 mU/mg of IgG and 7·8 vs. 20·0–46·2 lU/mg of IgG) C1q binding (0·42 vs. 0·67–1·89 arbitrary units) and C5a uptake (0·41 vs. 0·45–0·66% of activation) were lower in ClairYg® than in other preparations. Finally, intravenous infusion of ClairYg®, Gamunex® and Privigen® had no major effect on arterial blood pressure in spontaneously hypertensive rats. Conclusions Our results evidence some differences in the biological and biochemical properties among licensed liquid IVIg preparations.
format Online
Article
Text
id pubmed-3580880
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-35808802013-02-25 In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations Dhainaut, F Guillaumat, P-O Dib, H Perret, G Sauger, A de Coupade, C Beaudet, M Elzaabi, M Mouthon, L Vox Sang Blood Component Collection and Production Objective To compare in vitro and in vivo biological and biochemical properties of five liquid intravenous immunoglobulin (IVIg) preparations licensed for therapeutic use in Europe. Methods ClairYg® was compared in a blinded manner to four other liquid IVIg preparations licensed in Europe (Octagam®, Kiovig®, Gamunex®, Privigen®). Three batches of each preparation were tested, except for the IgG repertoires and the animal model. Results Levels of anti-A and anti-B antibodies were lower in ClairYg® (0·11/0·11) relative to a positive EDQM standard and Octagam® (0·11/0·08) than in other preparations (0·33–0·69/0·42–0·46). IgG in ClairYg® recognized 365 and 416 protein spots in HEp-2 cell and Escherichia coli protein extracts vs. 230–330 and 402–842 protein spots, respectively, for IgG in other preparations. IgA content (301 vs. 165–820 ng/mg of IgG), Factor XI and Factor XII antigen (0·46 vs. 0·85–2·40 mU/mg of IgG and 7·8 vs. 20·0–46·2 lU/mg of IgG) C1q binding (0·42 vs. 0·67–1·89 arbitrary units) and C5a uptake (0·41 vs. 0·45–0·66% of activation) were lower in ClairYg® than in other preparations. Finally, intravenous infusion of ClairYg®, Gamunex® and Privigen® had no major effect on arterial blood pressure in spontaneously hypertensive rats. Conclusions Our results evidence some differences in the biological and biochemical properties among licensed liquid IVIg preparations. Blackwell Publishing Ltd 2013-02 /pmc/articles/PMC3580880/ /pubmed/23003576 http://dx.doi.org/10.1111/j.1423-0410.2012.01648.x Text en © 2012 The Author(s). Vox Sanguinis © 2012 International Society of Blood Transfusion http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Blood Component Collection and Production
Dhainaut, F
Guillaumat, P-O
Dib, H
Perret, G
Sauger, A
de Coupade, C
Beaudet, M
Elzaabi, M
Mouthon, L
In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations
title In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations
title_full In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations
title_fullStr In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations
title_full_unstemmed In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations
title_short In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations
title_sort in vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations
topic Blood Component Collection and Production
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580880/
https://www.ncbi.nlm.nih.gov/pubmed/23003576
http://dx.doi.org/10.1111/j.1423-0410.2012.01648.x
work_keys_str_mv AT dhainautf invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT guillaumatpo invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT dibh invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT perretg invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT saugera invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT decoupadec invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT beaudetm invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT elzaabim invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations
AT mouthonl invitroandinvivopropertiesdifferamongliquidintravenousimmunoglobulinpreparations